Drug Trial Radar · NCT05588609
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
13
Actual
Start
Nov 17, 2022
Primary completion
Jul 3, 2025
Study completion Jul 3, 2025
Sponsor
- Lead sponsor
- Partner Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
Conditions
- NSCLC Harboring NRG1 Fusion
- Metastatic Castration-resistant Prostate Cancer
Interventions
Afatinib Oral TabletDrug
anti epidermal growth factor receptor (EGFR)/HER2 agent
Enzalutamide PillDrug
second-generation androgen receptor antagonist
Abiraterone acetate tabletsDrug
androgen synthesis inhibitor
MCLA-128Biological
full length IgG1 bispecific antibody targeting HER2 and HER3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Group A: Evaluate efficacy of zenocutuzumab in combination with afatinib in terms of response.Time frame: Every 8 weeks until study ends, approximately 2 years
- Group B: Evaluate efficacy of zenocutuzumab in combination with enzalutamide or abiraterone acetate in terms of Prostate-Specific antigen level ≥ 50% (PSA50) response.Time frame: Every 4 weeks until study ends, approximately 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
The Oncology Institute of Hope & Innovation
Whittier, California
Florida Cancer Specialists
Lake Mary, Florida
The Center for Cancer and Blood Disorders
Bethesda, Maryland
Memorial Sloan Kettering Cancer Center
New York, New York
TriHealth Cancer Institute
Cincinnati, Ohio
University Hospitals - Seidman Cancer Center
Cleveland, Ohio
Northwest Medical Specialties
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.